Fig 1: In vitro effect of PON-3. (A) Schematic design of in vitro experiments for in vitro testing of PON-3. (B) Effect of different doses of PON-3 on relative endothelial activation gene expression under TNF- a stimulation. (C) Effect of 500 ng/mL PON-3 on HUVECs under IL-6 treatment. The line at the 100% point represents the negative control. (D) Effect of 500 ng/mL PON-3 treatment of endothelial cells in combination with s H-CRP axSpA serum. The line at the 100% point represents the effect of healthy donor serum. Relative gene expression is represented as mean values±SD, with individual values. axSpA, axial spondyloarthritis; CRP, C reactive protein; HUVECs, human umbilical vein endothelial cells; IL, interleukin; PON3, paraoxonase 3, s H-CRP, sustained high CRP; TNF, tumour necrosis factor. *Significant differences, p<0.05; **Significant differences, p<0.01; ns, no significant.